NGNE
Neurogene Inc.Company Information
- Company Name
- Neurogene Inc.
- CIK
- CIK0001404644
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- NGNE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NGNE
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-26
- Last sale
- 2026-07-07
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 40,241
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 17,337,213
- Shares outstanding
- 22,552,032
- Ownership
- 76.88%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 7.82%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 112 | 124 | 104 | 71 | 59 | 71 | 137 | 67 | 111 | 150 | 148 | 25 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | - | - | - | 53 | ||||||
| Other Assets Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Short Term Investments | 113 | 119 | 165 | 194 | 216 | 222 | 176 | 72 | 43 | 19 | 49 | - | ||||||
| Prepaid Expense And Other Assets Current | 4 | 4 | 3 | 5 | 4 | 4 | 4 | 5 | 5 | 5 | 3 | - | ||||||
| Assets Current | 229 | 247 | 272 | 271 | 279 | 296 | 316 | 144 | 159 | 174 | 200 | 80 | ||||||
| Property Plant And Equipment Net | 12 | 13 | 13 | 13 | 14 | 15 | 15 | 16 | 16 | 16 | 17 | 0 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 9 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | - | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 244 | 263 | 289 | 288 | 297 | 315 | 336 | 164 | 180 | 195 | 223 | 90 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 4 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 5 | 2 | 2 | 2 | 3 | 1 | 2 | 2 | 2 | 3 | - | ||||||
| Accrued Liabilities Current | 15 | 11 | 11 | 9 | 9 | 7 | 10 | 10 | 7 | 7 | 17 | - | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Asset Acquisition Contingent Consideration Liability Current | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | - | ||||||
| Liabilities Current | 22 | 19 | 16 | 15 | 15 | 14 | 15 | 16 | 13 | 12 | 23 | 5 | ||||||
| Operating Lease Liability Noncurrent | 5 | 6 | 7 | 7 | 8 | 9 | 9 | 10 | 11 | 12 | 12 | 9 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Asset Acquisition Contingent Consideration Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities | 27 | 25 | 24 | 22 | 24 | 24 | 25 | 27 | 25 | 25 | 37 | 14 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 635 | 621 | 618 | 593 | 580 | 577 | 573 | 380 | 378 | 375 | 373 | 547 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Retained Earnings Accumulated Deficit | -418 | -384 | -353 | -328 | -307 | -285 | -262 | -243 | -223 | -204 | -187 | -472 | ||||||
| Stockholders Equity | 217 | 238 | 265 | 266 | 273 | 292 | 310 | 137 | 155 | 171 | 186 | -183 | ||||||
Temporary Equity | ||||||||||||||||||
| Liabilities And Stockholders Equity | 244 | 263 | 289 | 288 | 297 | 315 | 336 | 164 | 180 | 195 | 223 | 90 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 20 | ||||||
| Common Stock Shares Issued | 16 | 16 | 15 | 15 | 14 | 15 | 15 | 13 | 13 | 13 | 7 | 9 | ||||||
| Shares Outstanding | 16 | 16 | 15 | 15 | 14 | 15 | 15 | 13 | 13 | 13 | 13 | 9 | ||||||
| Series A1 Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Series A2 Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Series B Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Common Class A | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Common Class B | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNeurogene Inc. (NGNE) — SEC Financial Statements & Analysis
Neurogene Inc. (NGNE) is a pharmaceutical preparations company. Neurogene Inc. trades on Nasdaq as: NGNE. Neurogene Inc. (NGNE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Neurogene Inc. carries a market cap of $709.26M, a P/E ratio of -6.38x, a P/B ratio of 3.27x, a P/S ratio of 265.80x, an enterprise value of $596.45M, and an EV/EBITDA multiple of -5.04x. On profitability, it posts an operating margin of -9702.16%, a net margin of -8742.70%, a Return on Equity (ROE) of -45.32%, a Return on Assets (ROA) of -41.02%, and a Return on Invested Capital (ROIC) of -76.21%. Per share, it reports EPS of $-4.93, diluted EPS of $-4.93, free cash flow per share of $-3.89, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 31.66% year-over-year, and EPS growth of 22.92% year-over-year. On the balance sheet, it maintains a current ratio of 10.64x, a quick ratio of 10.48x, working capital of $207.41M, a debt-to-equity ratio of 0.13x, a debt ratio of 0.11, an interest coverage ratio of -60673.50x, free cash flow of $-87.71M (TTM), and net debt of $-112.82M. Figures sourced from SEC EDGAR.
- Market Cap
- $709.26M
- P/E TTM
- -6.38x
- EPS TTM
- $-4.93
- P/B TTM
- 3.27x
- ROE TTM
- -45.32%
- ROA TTM
- -41.02%
- Debt To Equity
- 0.13x
- Free Cash Flow TTM
- $-87.71M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Neurogene Inc. in?
Neurogene Inc. (NGNE) operates in the Pharmaceutical Preparations industry.
What exchange does NGNE trade on?
Neurogene Inc. (NGNE) trades on the Nasdaq.
When was Neurogene Inc. (NGNE)'s most recent SEC filing?
Neurogene Inc. (NGNE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is NGNE's market cap?
Neurogene Inc. (NGNE) has a market capitalization of $709.26M as of 2026-06-30.
What is NGNE's EPS (earnings per share)?
Neurogene Inc. (NGNE)'s trailing twelve month EPS is $-4.93 as of 2026-06-30.
What is NGNE's ROE (return on equity)?
Neurogene Inc. (NGNE)'s trailing twelve month Return on Equity (ROE) is -45.32% as of 2026-06-30.
What is NGNE's ROA (return on assets)?
Neurogene Inc. (NGNE)'s trailing twelve month Return on Assets (ROA) is -41.02% as of 2026-06-30.
What is NGNE's ROIC (return on invested capital)?
Neurogene Inc. (NGNE)'s trailing twelve month Return on Invested Capital (ROIC) is -76.21% as of 2026-06-30.
What is NGNE's EV/EBITDA?
Neurogene Inc. (NGNE)'s trailing twelve month EV/EBITDA is -5.04x as of 2026-06-30.